Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Chadi Al-Nawakil, Jerome Tamburini, Valerie Bardet, Nicolas Chapuis, Edward Bourry, Christian Roux, Sophie Park, Sylvain Choquet, François Dreyfus & Didier Bouscary. (2008) Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leukemia & Lymphoma 49:10, pages 2012-2014.
Read now
Read now
Ridvan Ali, Meral Beksac, Fahir Ozkalemkas, Vildan Ozkocaman, Atilla Ozkan, Tulay Ozcelik & Ahmet Tunali. (2007) Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. Leukemia & Lymphoma 48:7, pages 1426-1428.
Read now
Read now
Don M. Benson$suffix/text()$suffix/text() & Megan K. Smith. (2007) Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leukemia & Lymphoma 48:7, pages 1423-1425.
Read now
Read now
Articles from other publishers (23)
Pellegrino Musto, Vittorio Simeon, Katia Todoerti & Antonino Neri. (2016) Primary Plasma Cell Leukemia: Identity Card 2016. Current Treatment Options in Oncology 17:4.
Crossref
Crossref
Eirini Katodritou, Evangelos Terpos, Charikleia Kelaidi, Maria Kotsopoulou, Sossana Delimpasi, Marie-Christine Kyrtsonis, Argiris Symeonidis, Nikos Giannakoulas, Aikaterini Stefanoudaki, Dimitrios Christoulas, Christina Chatziaggelidou, Vassiliki Gastari, Nikos Spyridis, Evgenia Verrou, Pavlina Konstantinidou, Kostas Zervas & Meletios A. Dimopoulos. (2014) Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. American Journal of Hematology 89:2, pages 145-150.
Crossref
Crossref
Taiga Nishihori, Sarah M. Abu Kar, Rachid Baz, Melissa Alsina, Jean-Luc Harousseau & Mohamed A. Kharfan-Dabaja. (2013) Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 19:8, pages 1144-1151.
Crossref
Crossref
J.C. Titos-Arcos, J. León-Villar, F. de Arriba de la Fuente, M.J. Moreno Belmonte & M.D. Iranzo Fernández. (2012) Estudio observacional restrospectivo para evaluar la efectividad y seguridad de esquemas de tratamiento con bortezomib para el mieloma múltiple en nuestro hospital. Farmacia Hospitalaria 36:4, pages 275-281.
Crossref
Crossref
G. D'Arena, C.G. Valentini, G. Pietrantuono, R. Guariglia, M.C. Martorelli, G. Mansueto, O. Villani, D. Onofrillo, A. Falcone, G. Specchia, G. Semenzato, N. Di Renzo, L. Mastrullo, A. Venditti, F. Ferrara, A. Palumbo, L. Pagano & P. Musto. (2012) Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Annals of Oncology 23:6, pages 1499-1502.
Crossref
Crossref
Pellegrino Musto, Livio Pagano, Maria Teresa Petrucci, Fortunato Morabito, Tommaso Caravita, Francesco Di Raimondo, Luca Baldini, Patrizia Tosi, Sara Bringhen, Massimo Offidani, Paola Omede’, Antonino Neri, Fiorella D’Auria, Giovanni Battista Bochicchio, Michele Cavo, Mario Boccadoro & Antonio Palumbo. (2012) Primary plasma cell leukemia in the era of new drugs: Has something changed?. Critical Reviews in Oncology/Hematology 82:2, pages 141-149.
Crossref
Crossref
Daniel Lebovic, Ling Zhang, Melissa Alsina, Taiga Nishihori, Kenneth H. Shain, Daniel Sullivan, Jose L. Ochoa-Bayona, Mohamed A. Kharfan-Dabaja & Rachid Baz. (2011) Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience. Clinical Lymphoma Myeloma and Leukemia 11:6, pages 507-511.
Crossref
Crossref
Sumit Madan & Philip R. Greipp. 2011. Concise Guide to Hematology. Concise Guide to Hematology
287
306
.
Jennifer M. Bird, Roger G. Owen, Shirley D?Sa, John A. Snowden, Guy Pratt, John Ashcroft, Kwee Yong, Gordon Cook, Sylvia Feyler, Faith Davies, Gareth Morgan, Jamie Cavenagh, Eric Low & Judith Behrens. (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology 154:1, pages 32-75.
Crossref
Crossref
L. Pagano, C.G. Valentini, V. De Stefano, A. Venditti, G. Visani, M.T. Petrucci, A. Candoni, G. Specchia, C. Visco, E.M. Pogliani, F. Ferrara, P. Galieni, A. Gozzetti, L. Fianchi, M. De Muro, G. Leone, P. Musto & A. Pulsoni. (2011) Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Annals of Oncology 22:7, pages 1628-1635.
Crossref
Crossref
Flavio Albarracin & Rafael Fonseca. (2011) Plasma cell leukemia. Blood Reviews 25:3, pages 107-112.
Crossref
Crossref
Caterina Giovanna Valentini, Valentina Bozzoli, Luana Fianchi, Maria Teresa Voso, Gianluigi Di Paolantonio, Marianna Criscuolo, Giuseppe Leone, Luigi Maria Larocca & Livio Pagano. (2011) Primary plasma cell leukemia followed by testicular plasmacytoma. International Journal of Hematology 93:2, pages 224-227.
Crossref
Crossref
Gabriele Buda, Giovanni Carulli, Enrico Orciuolo, Elisa Cannizzo, Matteo Pelosini, Sara Galimberti & Mario Petrini. (2010) correspondence: CD23 expression in plasma cell leukaemia. British Journal of Haematology 150:6, pages 724-725.
Crossref
Crossref
Edward Libby, Dulcinea Candelaria‐Quintana, Hayan Moualla, Maryam Abdul‐Jaleel & Ian Rabinowitz. (2010) Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. American Journal of Hematology 85:9, pages 733-734.
Crossref
Crossref
Taimur Sher, Kena C. Miller, George Deeb, Kelvin Lee & Asher Chanan-Khan. (2010) Plasma cell leukaemia and other aggressive plasma cell malignancies. British Journal of Haematology 150:4, pages 418-427.
Crossref
Crossref
Giridharan Ramsingh, Paul Mehan, Jingqin Luo, Ravi Vij & Daniel Morgensztern. (2009) Primary plasma cell leukemia. Cancer 115:24, pages 5734-5739.
Crossref
Crossref
Tommasina Guglielmelli, Roberta Merlini, Emilia Giugliano & Giuseppe Saglio. (2009) Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell Leukaemia. Journal of Oncology 2009, pages 1-2.
Crossref
Crossref
Béla Telek, Leonóra Méhes, Péter Batár, Attila Kiss & Miklós Udvardy. (2008) Effective PAD (bortezomib, doxorubicine, dexamethasone) treatment of a patient with plasma cell leukaemia developed after autologous stem cell transplantation. Orvosi Hetilap 149:41, pages 1957-1959.
Crossref
Crossref
D. Lacruz Guzmán, C. Funes Vera, M. Martínez Penella, M.J. Morales Lara, V. Jorge Vidal & M.C. Mira Sirvent. (2008) Bortezomib como alternativa en el tratamiento de pacientes con gammapatías malignas. Farmacia Hospitalaria 32:5, pages 280-285.
Crossref
Crossref
Eirini Katodritou, Evgenia Verrou, Vassiliki Gastari, Christina Hadjiaggelidou, Evangelos Terpos & Konstantinos Zervas. (2008) Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?. Leukemia Research 32:7, pages 1153-1156.
Crossref
Crossref
D. Lacruz Guzmán, C. Funes Vera, M. Martínez Penella, M.J. Morales Lara, V. Jorge Vidal & M.C. Mira Sirvent. (2008) Bortezomib as an Alternative in the Treatment of Patients With Malignant Gammopathy. Farmacia Hospitalaria (English Edition) 32:5, pages 280-285.
Crossref
Crossref
Pellegrino Musto, Fausto Rossini, Francesca Gay, Vincenzo Pitini, Tommasina Guglielmelli, Giovanni D'Arena, Felicetto Ferrara, Nunzio Filardi, Roberto Guariglia & Antonio Palumbo. (2007) Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 109:11, pages 2285-2290.
Crossref
Crossref
Seok Jin Kim, Jeeyong Kim, Yunjung Cho, Bo Kyoung Seo & Byung Soo Kim. (2007) Combination Chemotherapy with Bortezomib, Cyclophosphamide and Dexamethasone may be Effective for Plasma Cell Leukemia. Japanese Journal of Clinical Oncology 37:5, pages 382-384.
Crossref
Crossref